文献速递帕金森病与运动障碍

帕金森病运动储备的时间动态及其相关因素与结局

Temporal Dynamics and Cross-Sectional and Longitudinal Factors Associated With Motor Reserve and Outcome in Patients With Parkinson Disease.
PubMed 文献 · Neurology · 2025-12-26

该回顾性观察性队列研究利用PPMI中566例初治帕金森病患者的系列DAT成像数据,采用残差法和交互法评估运动储备,发现规律体力活动与基线运动储备相关,且运动储备介导了体力活动对运动症状改善的效应;早期平均运动储备(而非基线值)可预测长期运动结局,充足药物和持续规律体力活动与早期运动储备下降较慢相关。

要点

  • 早期平均运动储备而非基线值可预测长期运动结局。
  • 规律体力活动和充足药物是可改变的运动储备维持因素。
  • 运动储备介导体力活动对运动症状改善的效应。

核心结论

  • 诊断后早期维持运动储备可强烈预测有利的长期运动结局,充足治疗和规律体力活动支持这一维持。

研究设计与样本

  • 回顾性观察性队列研究,纳入566例初治帕金森病患者,中位年龄62.3岁(四分位距56.3-69.6),女性占33.7%,基于PPMI系列DAT成像数据。

主要发现

  • 基线时规律体力活动在两种方法中均与运动储备显著相关,中介分析表明运动储备 largely 介导了体力活动对运动症状改善的效应。
  • 纵向分析中,充足药物和持续规律体力活动水平与运动储备早期年份下降较慢强烈相关。
  • 早期年份平均运动储备(而非基线值)是长期运动结局的强预测因子:Cox模型中Hoehn/Yahr分期3的风险比=0.50(95%CI 0.37-0.66);线性混合效应模型中MDS-UPDRS Part 3评分的固定效应标准化交互系数=-0.57(95%CI -0.79至-0.35)。
  • 上述发现通过倾向性评分匹配进一步验证。

临床怎么用

  • 在帕金森病早期应重视维持运动储备,鼓励规律体力活动和充足药物治疗以支持长期运动结局。

局限性

  • 研究仅纳入早期初治帕金森病患者,需在后期阶段进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: "Motor reserve" refers to the brain's dynamic resilience against dopaminergic degeneration in Parkinson disease (PD). However, its clinical significance remains unclear because of critical limitations, including the lack of data on its longitudinal trajectories. Using Parkinson's Progression Markers Initiative data with serial dopamine transporter (DAT) imaging from the drug-naive stage, we investigated its trajectories, determinants, and prognostic implications. METHODS: This retrospective observational cohort study assessed motor reserve using 2 complementary approaches. The residual-based approach calculated deviations in Movement Disorders Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3 scores from expected values derived from a linear regression model incorporating putamen DAT specific binding ratio (putamen SBR), age, sex, and disease duration. The interaction-based approach extended this model by introducing interaction terms between putamen SBR and each factor, analyzing the corresponding β coefficients. We examined motor reserve's cross-sectional associations with clinical parameters, its mediation effects, and its longitudinal trajectories-up to 4 years-based on DAT imaging data availability, while identifying factors influencing its changes. Finally, we assessed its impact on long-term prognosis using Cox proportional hazards and linear mixed-effects models (LMEMs). RESULTS: We included 566 drug-naive patients with PD (median age 62.3 [interquartile range 56.3-69.6] years; 33.7% female). At baseline, regular physical activity was significantly associated with motor reserve in both approaches, with mediation analysis indicating that motor reserve largely mediated the effect of physical activity on motor symptom improvement. Longitudinally, adequate medication and sustained regular physical activity levels were strongly associated with a slower early-years decline in motor reserve. It is important to note that early-years average motor reserve, not the baseline value, was a strong predictor of long-term motor outcomes (Cox: Hoehn/Yahr stage 3, hazard ratio = 0.50, 95% CI 0.37-0.66; LMEMs: MDS-UPDRS Part 3 score, fixed-effects standardized interaction coefficient = -0.57, 95% CI -0.79 to -0.35). These findings were further validated through propensity score matching. DISCUSSION: Maintaining motor reserve in the early years after diagnosis strongly predicts favorable long-term motor outcomes, with adequate treatment and regular physical activity-both modifiable factors-supporting this maintenance. Because our study includes early-stage, drug-naive PD, further research in later stages is warranted. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov (NCT01141023). A link to the trial registry page is clinicaltrials.gov/ct2/show/NCT01141023.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Tsukita K, Kikuya A, Yoshimura K, et al. Temporal Dynamics and Cross-Sectional and Longitudinal Factors Associated With Motor Reserve and Outcome in Patients With Parkinson Disease. Neurology. 2025. PMID: 41453126. doi:10.1212/WNL.0000000000214475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。